Clinical trial · no report yet · Phase 2
EMERALD-Y90
A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE
- NCT06040099 ↗
- Active not recruiting
- AstraZeneca
- 19 commentary sources found
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| YouTube | 10 | |
| Podcasts | 5 | |
| X threads | 4 |
The trial
ClinicalTrials.gov- Official title
- Phase II Single-Arm Study of Durvalumab and Bevacizumab Following Transarterial Radioembolization Using Yttrium-90 Glass Microspheres (TheraSphere™) in Unresectable Hepatocellular Carcinoma Amenable to Locoregional Therapy
- Phase
- Phase 2
- Status
- Active not recruiting
- Conditions
- Hepatocellular Carcinoma (HCC)
- Interventions
- Durvalumab; Bevacizumab; Transarterial Radioembolization (TARE)
- Arms
- Yttrium 90 glass microspheres TARE in combination with Durvalumab and Bevacizumab · Experimental
- Enrollment
- 58
- Primary outcomes
- Progression Free Survival (PFS)
- Sponsor
- AstraZeneca
- Start
- Feb 13, 2024
- Primary completion
- Jun 30, 2026
- Results posted
- No
- Registry record
- NCT06040099 · updated Sep 21, 2026
Publications
linked from the registry- Pabon CM, Kumar-Sharma P, Spieler BO, Tuerff D, Datta J, Hosein PJ. Identifying Subsets of Patients with Non-immunogenic Gastrointestinal Cancers for Checkpoint Immunotherapy. Surg Oncol Clin N Am. 2026 Apr;35(2):347-365. doi: 10.1016/j.soc.2025.10.008. Epub 2026 Jan 14. PubMed 41903993